Shiming M. He

No. 8 Xishiku Street
Beijing, 100034, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

UCtracker: A Deep Learning-Based DNA Methylation Model for Noninvasive Diagnosis and Recurrence Surveillance of Urothelial Carcinoma in a Prospective Study.

UCtracker: A Deep Learning-Based DNA Methylation Model for Noninvasive Diagnosis and Recurrence Surveillance of Urothelial Carcinoma in a Prospective Study.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 26, 2026

Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.

Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.

Journal: Clinical and experimental medicine

Published: January 03, 2026

Cytoreductive radical prostatectomy in patients with high-volume metastatic prostate cancer achieving deep biochemical response to contemporary systemic therapy: a multicentre, prospective cohort study.

Cytoreductive radical prostatectomy in patients with high-volume metastatic prostate cancer achieving deep biochemical response to contemporary systemic therapy: a multicentre, prospective cohort study.

Journal: BMC medicine

Published: December 24, 2025

Pathology-Driven Genomic Panels for Personalized Prognostic Stratification and Exploratory Therapeutic Prediction in Clear-Cell Renal Cell Carcinoma with Tumor Thrombus.

Pathology-Driven Genomic Panels for Personalized Prognostic Stratification and Exploratory Therapeutic Prediction in Clear-Cell Renal Cell Carcinoma with Tumor Thrombus.

Journal: Diagnostics (Basel, Switzerland)

Published: December 16, 2025

Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.

Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.

Journal: Clinical epigenetics

Published: September 24, 2025

RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated regulation of ZO2.

RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated regulation of ZO2.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 10, 2025

Extrachromosomal DNA and cancer: function, formation, and clinical implications.

Extrachromosomal DNA and cancer: function, formation, and clinical implications.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 15, 2025

Single-cell RNA sequencing identifies potential critical prognostic biomarkers in bladder carcinoma.

Single-cell RNA sequencing identifies potential critical prognostic biomarkers in bladder carcinoma.

Journal: Scientific reports

Published: June 09, 2025

LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.

LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.

Journal: Clinical and experimental medicine

Published: May 21, 2025

Development and Validation of a Novel Plasma Metabolomic Signature for the Detection of Renal Cell Carcinoma.

Development and Validation of a Novel Plasma Metabolomic Signature for the Detection of Renal Cell Carcinoma.

Journal: European urology

Published: May 16, 2025

Fumarate hydratase-deficient renal cell carcinoma: high intratumoral and peritumoral CD4-positive T cell infiltration density and high PD-L1 expression.

Fumarate hydratase-deficient renal cell carcinoma: high intratumoral and peritumoral CD4-positive T cell infiltration density and high PD-L1 expression.

Journal: World journal of urology

Published: May 06, 2025

Comparative analysis of clinicopathological characteristics and prognostic outcomes in fumarate hydratase-deficient renal cell carcinoma versus high-grade papillary renal cell carcinoma.

Comparative analysis of clinicopathological characteristics and prognostic outcomes in fumarate hydratase-deficient renal cell carcinoma versus high-grade papillary renal cell carcinoma.

Journal: Translational andrology and urology

Published: April 05, 2025

Showing 1-12 of 69

Last Updated: 09/26/2026